ClinicalTrials.gg
CompletedNCT01423110Updated Dec 17, 2020

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

A Phase 2 interventional study of BYM338 and Placebo in Sporadic Inclusion Body Myositis, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.

Enrollment
21st of 27
14 · median 24
Started
2011
the only one that year
Phase 2
7 of 37
none open now
Registered
13th of 37
by date
Lead sponsor
6 of 37
Novartis Pharmaceuticals

Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 2, and was the 13th registered.

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Open to participants now

4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Myositis, Inclusion Body with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis

03

Conditions studied

  • Sporadic Inclusion Body Myositis

Keywords

  • sporadic Inclusion Body Myositis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females aged 40-80 with a confirmed diagnosis of sporadic Inclusion Body Myositis

Exclusion criteria

Exclusion Criteria:

  • Unable to walk at least 3 meters without assistance from another person
  • Use of oral beta agonists, oral , androgens or androgen inhibitors, or intravenous gamma globulin in the last 6 months
  • patients with a history or presence of renal impairment and/or liver disease

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    BYM338

    Biological: BYM338

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalBYM338
  • BiologicalPlacebo
06

What researchers measure

Primary outcomes

  1. Effect of BYM338 on Thigh Muscle Volume by MRI

    Change in thigh muscle volume

    Time frame: 8 weeks

Secondary outcomes

  1. Effect of BYM338 on muscle function by 'Timed Get Up and Go' test

    Change in muscle function measured on scale by test results

    Time frame: 8 weeks

07

Study locations

3 sites
  • Novartis Investigative Site
    Scottsdale, Arizona, United States
  • Novartis Investigative Site
    Kansas City, Kansas, United States
  • Novartis Investigative Site
    Boston, Massachusetts, United States
08

References and documents

Publications

  • Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ, Roubenoff R, Tseng BS, Greenberg SA. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014 Dec 9;83(24):2239-46. doi: 10.1212/WNL.0000000000001070. Epub 2014 Nov 7. PubMed 25381300 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2011
First posted
Aug 25, 2011
Start
Aug 2011
Primary completionActual
May 2012
CompletionActual
May 2012
Results delay requested
Aug 20, 2020
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01423110
Responsible party
Sponsor
First posted
Aug 25, 2011
Start date
Aug 2011
Primary completion
May 2012
Completion
May 2012
Last update
Dec 17, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion